Skip to main navigation
Skip to search
Skip to main content
Northwestern Scholars Home
Help & FAQ
Home
Experts
Organizations
Research Output
Grants
Core Facilities
Research Data
Search by expertise, name or affiliation
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
for the SELECT Trial Investigators*
Medicine, Endocrinology Division
Research output
:
Contribution to journal
›
Article
›
peer-review
1494
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
A1 Receptor
14%
Adverse Cardiovascular Events
14%
Adverse Events
14%
Body Mass Index
14%
Cardiovascular Outcomes
100%
Cardiovascular Risk
14%
Confidence Interval
14%
Diabetes
14%
Event Analysis
14%
Exposure Time
14%
Glucagon-like
14%
Hazard Ratio
14%
History of Diabetes
14%
Nonfatal Myocardial Infarction
28%
Nonfatal Stroke
28%
Novo Nordisk
14%
Obesity
100%
Once-weekly
14%
Overweight or Obesity
14%
Patients with Diabetes
14%
Placebo
57%
Placebo Groups
28%
Randomized Placebo-controlled Trial
14%
Receptor Agonist
14%
Semaglutide
100%
Subclinical Cardiovascular Disease
28%
Subcutaneous Semaglutide
28%
Superiority Trial
14%
Without Diabetes
100%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
11%
Cardiovascular Disease
22%
Cardiovascular Risk
11%
Cerebrovascular Accident
22%
Glucagon Like Peptide 1 Receptor Agonist
11%
Heart Infarction
22%
Placebo
77%
Semaglutide
100%